Zainab Almansour | Immunology and Molecular Biology | Research Excellence Award

Assoc. Prof. Dr. Zainab Almansour | Immunology and Molecular Biology | Research Excellence Award

King Faisal University | Saudi Arabia

Dr. Zainab H. Almansour is a dynamic academic and researcher with extensive expertise in immunology, antibody engineering, molecular bioscience, and cell biology. With a strong foundation in scientific research and teaching, she demonstrates exceptional analytical, leadership, and communication skills, effectively conveying complex concepts to diverse audiences. Her professional experience spans roles as Associate and Assistant Professor, as well as postdoctoral research, with a focus on fostering student development through innovative teaching methods and virtual enrichment programs. Dr. Almansour has contributed to multiple scientific and administrative initiatives, including curriculum development, accreditation committees, and academic guidance, while maintaining active engagement in laboratory research employing techniques such as phage bio-panning, protein analysis, molecular biology, cell culture, flow cytometry, and bioinformatics. She holds multiple patents and actively pursues professional growth through advanced training in AI applications, data analytics, and drug development, reflecting her commitment to innovation and excellence in research and education.

Citation Metrics (Google Scholar)

6000
4000
2000
200
100
50
0

Citations
5,725

Documents
149

h-index
44

i10-index
96

Citations

Documents

h-index

i10-index

Featured Publications

Kimberly Gilmour | Immunology Cellular Interactions | Women Researcher Award

Dr. Kimberly Gilmour | Immunology Cellular Interactions | Women Researcher Award

Great Ormond Street Hospital | United Kingdom

Kimberly Coughlan Gilmour is a leading expert in immunology, molecular diagnostics, and cell-based therapeutic development. Her early academic work contributed foundational insights into cytokine signaling, particularly the regulation of the Interferon Regulatory Factor-1 (IRF-1) gene and the signal transduction pathways activated by prolactin and interleukin-2. During her postdoctoral research, she investigated mechanisms governing thymocyte proliferation and differentiation using retroviral manipulation of murine thymic organ cultures, advancing understanding of T-cell development.

Gilmour has played a pivotal role in the evolution of clinical immunology diagnostics, leading the development of national services for the molecular diagnosis of primary immunodeficiency disorders. She has been instrumental in translating complex research methodologies—including gene expression analysis, retroviral and lentiviral transduction, and thymus tissue culture—into routine clinical tools that directly inform patient management. Her work supports post-treatment monitoring for haematopoietic stem cell transplantation, gene therapy, and targeted antibody-based interventions.

As a leader in cell therapy, she has overseen the implementation of advanced cellular manufacturing processes and supervised the clinical authorization of personalized therapeutic products. Her career integrates immunogenetics, translational science, and cellular therapy innovation, significantly shaping clinical practice for paediatric patients with rare and complex immune disorders.

Profiles: Scopus | Orcid

Featured Publications:

  • Maimaris, J., Roa-Bautista, A., Sohail, M., et al. (2025). Griscelli Syndrome Type 2: Comprehensive analysis of 149 new and previously described patients with RAB27A deficiency. Journal of Clinical Immunology, 45(50).

  • Author(s) Unknown. (2025). Safety and diagnostic utility of brain biopsy and metagenomics in decision-making for patients with inborn errors of immunity (IEI) and unexplained neurological manifestations. Journal of Clinical Immunology, 45, 86.

  • Booth, C., Masiuk, K., Vazouras, K., Fernandes, A., Xu-Bayford, J., Campo Fernandez, B., Roy, S., Curio-Penny, B., Arnold, J., Terrazas, D., Reid, J., Gilmour, K. C., Adams, S., Mediavilla, E. A., Mhaldien, L., O’Toole, G., Ahmed, R., Garabedian, E., Malech, H., De Ravin, S. S., Moore, T. B., De Oliveira, S., Pellin, D., Lin, T.-Y., Dang, T. T., Cornetta, K., Hershfield, M. S., Hara, H., Thrasher, A. J., Gaspar, H. B., & Kohn, D. B. (2025). Long-term safety and efficacy of gene therapy for adenosine deaminase deficiency. New England Journal of Medicine, 393(15), 1486–1497.

  • Guardo, D., Mishra, A. K., Rashed, H., Gilmour, K. C., Adams, S., Pinner, D., Sauer, M., Vora, A., Veys, P., Pavasovic, V., Rao, K., & Qasim, W. (2025). Long-term outcomes of genome-edited “universal” CAR19 T cells for relapsed/refractory B-ALL at a single pediatric center. Blood Advances, 9(18), 4750–4754.

 

Zhihua Wu | Allergen | Best Researcher Award

Mr. Zhihua Wu | Allergen | Best Researcher Award

Nanchnag University | China

Dr. Zhihua Wu is a leading researcher in the field of food science and nanobiotechnology, with a focus on food protein processing, allergen characterization, and functional food development. His work explores the structural and immunological properties of food allergens, particularly those derived from peanuts, soybeans, and almonds, aiming to elucidate mechanisms underlying allergenicity and cross-reactivity. He employs advanced analytical tools such as mass spectrometry, metabolomics, and molecular modeling to investigate how food processing, polyphenol interactions, and roasting alter protein structures and immune responses. Dr. Wu’s recent studies have provided key insights into epitope localization and allergen modification for risk reduction in plant-based foods. His ongoing research projects, funded by major Chinese national programs, include developing safety evaluation and risk mitigation techniques for plant-derived food resources and mapping IgE-binding epitopes of 2S albumins. He also contributes to the understanding of food flavor chemistry, especially changes in tea aroma compounds during processing and storage. Recognized through multiple provincial and national science awards, Dr. Wu’s research advances the interface of food safety, protein chemistry, and functional nutrition, offering innovative strategies for producing hypoallergenic and health-promoting food products.

Profile: Scopus

Featured Publications:

Wu, Z., Gao, K., Geng, Q., Hu, C., Zhang, W., Li, X., Tong, P., Yang, A., & Chen, H. (2025). Impact of the polyphenol structure on the allergenic potential of the peanut allergen Ara h 2. Journal of Agricultural and Food Chemistry, 73(28), 17967–17979.

Hu, C., Luo, Q., Zhou, L., Zhu, W., Gao, K., Geng, Q., Li, X., Yang, A., Tong, P., Wu, Z., & Chen, H. (2025). Purification of Pru du 6 from almond and its cross-reactivity with Gly m 6 from soybean. International Journal of Molecular Sciences, 26(11), 5425.

Zhang, Y., Zhang, J., Li, X., Yang, A., Tong, P., Wu, Z., & Chen, H. (2025). Untargeted metabolomics reveals changes in serum metabolism in peanut-allergic mice treated by raw and roasted peanuts. Food Science and Human Wellness.

Zhou, W., Geng, Q., Zhang, Y., Zhou, X., Wu, Z., Chen, H., & El-Sohaimy, S. (2024). The flavonoid-allergen interaction and its influence on allergenicity. Food Bioscience, 61, 104939. h

Zhang, Y., Geng, Q., Song, M., Li, X., Yang, A., Tong, P., Wu, Z., & Chen, H. (2024). The structure and potential allergenicity of peanut allergen monomers after roasting. Food & Function, 15, 2577–2586.

Alejandro Rojas | Immunology Cellular Interactions | Best Researcher Award

Assist. Prof. Dr. Alejandro Rojas | Immunology Cellular Interactions | Best Researcher Award

Assist. Prof. Dr. Alejandro Rojas | Austral University of Chile | Germany

Dr. Alejandro Alfredo Rojas Fernández is a distinguished Chilean molecular biotechnologist and neuroscientist, currently serving as CEO of Berking Theranostics UG in Hamburg, Germany, and Assistant Professor at the Universidad Austral de Chile. With over two decades of research spanning neurodegeneration, immunology, and viral pathogenesis, Dr. Rojas-Fernández has emerged as a leading expert in molecular diagnostics and theranostics. His innovative work has significantly impacted global health, notably through his contributions to SARS-CoV-2 research and senolytic therapies. A dual academic and entrepreneur, he bridges fundamental science and clinical application, actively publishing in top-tier journals such as Nature Aging, Molecular Psychiatry, and Journal of Cell Biology. Fluent in interdisciplinary collaboration, his efforts have been internationally recognized with multiple honors. With a passion for translational science, Dr. Rojas-Fernández continues to inspire the next generation of biomedical innovators through mentorship and leadership in biotechnology and neuroscience.

Publication Profile:

Orcid

Education:

Dr. Alejandro Rojas-Fernández earned his PhD in Biology from the University of Konstanz, Germany (2006–2010), where his research focused on the regulation of Hdm2/HdmX-mediated ubiquitination and neddylation—mechanisms central to protein stability and cancer biology. Prior to his doctorate, he completed his engineering degree in Molecular Biotechnology (2004–2005) and his B.Sc. in Molecular Biotechnology Engineering (2000–2004) at the Faculty of Sciences, University of Chile—one of Latin America’s leading research institutions. His multidisciplinary education integrates molecular biology, neurobiology, immunology, and translational medicine, equipping him with the foundational and advanced tools to tackle complex biomedical challenges. Dr. Rojas-Fernández’s academic training has been marked by academic excellence and international mobility, enabling him to collaborate and lead research projects across Europe and Latin America.

Experience:

Dr. Rojas-Fernández brings over 20 years of experience in translational biomedical research, academia, and biotech innovation. As CEO of Berking Theranostics UG, he spearheads the development of personalized diagnostic platforms and therapeutics, with a focus on neurodegenerative and inflammatory diseases. In his role as Assistant Professor at Universidad Austral de Chile (20% appointment), he leads the Medical Biotechnology Laboratory within the Centre for Interdisciplinary Studies on the Nervous System (CISNe), contributing to scientific training and cutting-edge research. He previously trained and collaborated at institutions such as the University of Dundee, University of Queensland, and University of Constance, advancing molecular mechanisms of SUMOylation, proteostasis, inflammasome biology, and viral-host interactions. His interdisciplinary expertise allows him to translate complex cellular insights into tangible clinical applications, and his leadership has resulted in high-impact publications, product pipelines, and strategic biotech partnerships in Europe and Latin America.

Awards and Honors:

Dr. Rojas-Fernández has received multiple prestigious honors recognizing his innovative biomedical research. In February 2025, he was named “Innovator of the Month” by Hamburg Invest for groundbreaking biotech contributions in Germany. He was awarded the Medal of the City of Valdivia for his vital role in controlling the SARS-CoV-2 pandemic, one of the highest local honors in Chile. Additionally, he received the 2nd of October Medal for Science and Innovation, recognizing his scientific leadership in Chile’s Los Ríos region. These accolades underscore his impact on global public health, neurodegenerative research, and biotechnology entrepreneurship. His consistent recognition reflects a career dedicated to translational excellence, fostering international collaboration, and advancing science for the benefit of society. His scientific achievements continue to inspire innovation and interdisciplinary approaches within the global scientific community.

Research Focus:

Dr. Alejandro Rojas-Fernández’s research centers on cellular stress responses, ubiquitin/SUMO signaling, neurodegeneration, and host-pathogen interactions. A core focus is the molecular crosstalk between autophagy, protein quality control, and inflammasome activation in brain and immune cells. He has made significant advances in understanding the effects of SARS-CoV-2 on microglia, mechanisms of senescence in aging brains, and nanobody-based viral neutralization. His studies also explore the intersection of endoplasmic reticulum stress and neurodegenerative pathways, using high-content screening and proteomics to uncover therapeutic targets. He actively translates molecular insights into diagnostics and theranostic tools, positioning him at the forefront of personalized medicine. As CEO of a biotech startup, he is developing platforms that integrate biomarker discovery with AI for neuroinflammation profiling. His research bridges fundamental biology and clinical applications, promoting innovative therapies for Alzheimer’s, Parkinson’s, cancer, and viral infections.

Publications Top Notes: 

  1. Negative Modulation of Macroautophagy by Stabilized HERPUD1…Front Cell Dev Biol, 2022

  2. SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia…Mol Psychiatry, 2022

  3. The p97/VCP segregase is essential for arsenic-induced degradation of PML…J Cell Biol, 2023

  4. Lack of Parkinsonian Pathology after Proteasome Inhibitor Injection…Front Aging Neurosci, 2021

  5. NSPA modulates postsynaptic NMDAR stability…BMC Biol, 2020

  6. Role of PSMD14 in Golgi-to-ER transport and APP processingCells, 2020

  7. WDR90 in NLRC4 inflammasome and Salmonella resistanceDev Comp Immunol, 2019

  8. Proteomic identification of APC interaction partnersMol Cancer Res, 2019

  9. DHX15 regulates CMTR1-dependent gene expressionLife Sci Alliance, 2018

  10.  Membrane ruffling by polarized stim1 and orai1Sci Reports, 2017

Conclusion:

Dr. Alejandro Alfredo Rojas Fernández stands out as a pioneering researcher who consistently delivers scientifically rigorous, socially impactful, and clinically relevant work. His career spans critical sectors—basic research, applied biotechnology, and public health—making him a model example of the translational scientist. With accolades from both European and Latin American institutions and a track record of high-impact publications, Dr. Rojas exemplifies what it means to be a globally relevant and community-driven scientist. His work during the COVID-19 pandemic, innovations in molecular neuroscience, and leadership in therapeutic biotechnology underscore his immense value to the global research community. In conclusion, he is not only a suitable but a highly deserving candidate for the Best Researcher Award.

Marco Leitzke | immunology | Best Researcher Award

Dr. Marco Leitzke | immunology | Best Researcher Award

Dr. Marco Leitzke, Helios clinics, Germany

Dr. Marco Leitzke, born in 1970 in Karl-Marx-Stadt, Germany, is a senior anesthesiologist and pioneering researcher in neuromodulation and post-viral syndromes. He has served as Senior Consultant in Anesthesiology and Intensive Care at Helios Clinic Leisnig since 2015 and has extensive experience in pain therapy and palliative medicine. Renowned for his innovative studies on autonomic dysfunction, Dr. Leitzke has published extensively on cholinergic neurotransmission, COVID-19 coagulopathy, and vagus nerve stimulation. His recent focus on Long COVID as a disorder of disrupted acetylcholine signaling has gained significant scientific attention. With a dual career in clinical practice and experimental research, he bridges the gap between bedside and bench. His work earned him accolades, including a Poster Award at the 1st Long COVID Congress in Jena. Passionate about translational medicine, Dr. Leitzke continues to drive forward the understanding and treatment of complex neuroimmune disorders.

Publication Profile: 

Google Scholar

Scopus

Education:

Dr. Leitzke’s medical education and specialization reflect a deep commitment to anesthesiology and neurobiological research. He became a board-certified specialist in anesthesiology in 2006 and has built on this foundation with focused training in advanced pain management, ultrasound-guided interventions, and emergency medicine. He undertook specialized pain therapy training in 2015 and interventional pain techniques in 2014. In 2019, he began training as an Antibiotic Stewardship (ABS) expert physician, further demonstrating his holistic approach to patient safety and infection control. He also completed a transthoracic echocardiography course in 2018, showcasing his commitment to continuous learning and cross-disciplinary skills. This diverse academic background provides the basis for his translational research into neuroimmune and autonomic disorders, with a strong emphasis on clinical application. His combination of anesthesiology, ultrasound, pain therapy, and experimental neurobiology positions him as a uniquely skilled researcher bridging clinical practice and neuroscience.

Experience:

Dr. Marco Leitzke brings over two decades of clinical experience, predominantly in anesthesiology, intensive care, pain therapy, and palliative medicine. Since 2015, he has held the position of Senior Consultant at the Helios Clinic in Leisnig, where he leads interdisciplinary efforts in patient care and clinical innovation. Prior to this, he served as Senior Consultant at Asklepios Clinic Weißenfels from 2011 to 2014, while also operating as a freelance physician in Zeitz. His professional focus spans acute and chronic pain, complex anesthesia procedures, and critical care management, underpinned by a solid emergency medicine foundation gained since 2001. His hands-on experience with ultrasound-guided interventions, vagal modulation therapies, and autonomic diagnostics directly informs his research into the pathophysiology of post-viral syndromes. The integration of clinical insight and scientific exploration marks him as a dual-domain expert, fostering new therapeutic approaches rooted in both laboratory evidence and patient outcomes.

Research Focus:

Dr. Leitzke’s research centers on cholinergic neurotransmission and its impairment in acute and chronic post-viral conditions, particularly Long COVID. His central hypothesis suggests that autonomic dysfunction and neuromodulatory imbalance—specifically, disruption of the vagus nerve and acetylcholine pathways—underlie many post-viral symptoms. Through translational models using animal studies and human imaging, he explores therapeutic modulation, including vagal nerve stimulation and nicotine administration, to restore autonomic balance. His research extends to the role of NF-κB activation in COVID-19-associated coagulopathy, suggesting molecular pathways that link inflammation, clotting, and neuroimmune dysfunction. A hallmark of his work is the use of advanced imaging techniques (e.g., PET scans) to quantify cerebral receptor activity, particularly α7 nicotinic acetylcholine receptors. This integrative and experimental approach offers new perspectives on diagnostics and treatment in neuroimmune conditions, making his work highly relevant to both the scientific and medical communities in the era of post-COVID syndromes.

Publications Top Notes:

  1. 📖 Long COVID – A Critical Disruption of Cholinergic Neurotransmission? (Springer Nature, 2025)

  2. 📖 Is the Post-COVID-19 Syndrome a Severe Impairment of Acetylcholine-Orchestrated Neuromodulation That Responds to Nicotine Administration? (Springer Nature, 2023)

  3. 🏅 COVID-19 – The Ultimate NF-κB Rush and the Crucial Importance of Nicotinic Acetylcholine Receptors (Poster Award, Long COVID Congress, 2022)

  4. 🔬 Experimental Design for PET Detection of α7nAChR Under Gastric Vagus Nerve Stimulation in Piglets (DAS PLUS AN SCHUTZ, 2022)

  5. 🧠 The Viral Accelerated NF-κB Pathway and COVID-19-Associated Coagulopathy – A Case Report (Fortune Journals, 2021)

  6. 🧪 Afferent Vagal Stimulation via Gastric Electrical Stimulation Alters Sympathetic-Vagal Balance in Pigs – A Pilot Trial (Journal of Biological Regulators, 2021)

  7. ⚖️ Autonomic Balance Determines the Severity of COVID-19 Courses (Springer Nature, 2020)

  8. 🧮 A Semi-Automated Algorithm for Hypothalamus Volumetry in 3 Tesla MRI (Psychiatry Research: Neuroimaging, 2018)

  9. 🧬 Image-Derived Input Function for (-)-[18F]Flubatine Using a Digital PET System (European Journal of Nuclear Medicine, 2024)

  10. 💊 What Is the Impact of Nicotine on the Post-COVID-19 Syndrome? – A Case Series (Preprint, 2025)

Conclusion:

Dr. Marco Leitzke is a highly deserving candidate for the Best Researcher Award due to his pioneering contributions to understanding and treating Long COVID and neuroimmune disorders. His strong publication record, interdisciplinary approach, and clinical insight mark him as a leading figure in his field. With enhanced international collaboration and clinical validation of his findings, his impact could be even greater. Overall, his research is timely, innovative, and of substantial scientific and societal importance.

Alaka Sahoo | Immunology Cellular Interactions | Young Researcher Award

Mrs. Alaka Sahoo | Immunology Cellular Interactions | Young Researcher Award

Mrs. Alaka Sahoo, Siksha’O’ Anusandhan University, India

Dr. Alaka Sahoo is a dedicated young researcher in the field of Biotechnology with a focus on translational and clinical research. She holds a Ph.D. in Biotechnology from Siksha ‘O’ Anusandhan University, Odisha, with a CGPA of 8.90. With over 17 publications, including 11 research articles and 3 high-impact reviews, Dr. Sahoo has significantly contributed to oral disease therapeutics and antimicrobial studies. She demonstrates expertise in multi-omics analysis, drug discovery, and natural product-based therapy. A recipient of prestigious awards such as the Lalchand Women Entrepreneurs Award (2024), she is also a life member of reputed organizations like the British Society for Antimicrobial Chemotherapy. Her innovative approach to disease management using phytochemicals and peptides sets her apart as a rising talent in biomedical research.

Publication Profile: 

Google Scholar

Scopus

Orcid

✅ Strengths for the Award:

  1. Strong Publication Record:

    • 17 publications including 11 original research, 3 reviews, and 2 book chapters, showcasing depth and breadth.

    • 7 papers as first or corresponding author—indicating independent research capability.

    • Research in high-impact journals like Frontiers in Microbiology, Journal of Ethnopharmacology, Nanomaterials, and Chemistry & Biodiversity.

  2. Innovative & Multidisciplinary Research:

    • Integrates multi-omics, computational modeling, clinical dermatology, and natural products.

    • Focus on oral inflammatory diseases, antimicrobial peptides, and drug delivery systems.

  3. Academic Excellence & Research Training:

    • Ph.D. with 8.90 CGPA, and M.Sc. with 87.07% marks.

    • Expertise in BSL-2+ lab work, PCR, ELISA, microbial culture, and molecular docking.

  4. Awards & Recognition:

    • Lalchand Women Entrepreneurs Award (2024).

    • MSME-Idea Hackathon Innovation Award, Govt. of India.

  5. Global and National Engagement:

    • Life member of the British Society for Antimicrobial Chemotherapy (UK).

    • Demonstrates leadership in science entrepreneurship and women in research.

🛠️ Areas for Improvement:

  1. Expanded International Collaboration:

    • Building long-term research partnerships with international labs could increase global visibility.

  2. Patent/Technology Transfer Efforts:

    • While publications are strong, translating research into patents or commercial products will further strengthen applied impact.

  3. Focused Project Leadership:

    • Leading large interdisciplinary projects or acquiring independent grants will showcase funding leadership.

🎓 Education:

Dr. Alaka Sahoo has pursued a progressive academic path in Biotechnology. She earned her Ph.D. in Biotechnology from the School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan Deemed University, Odisha, completing her research with a notable 8.90 CGPA. Her thesis focused on “Therapeutic Opportunities for Oral Lichen Planus: An Integrated Multi-Omics Approach to Drug Discovery” under the guidance of Prof. (Dr.) Maitreyee Panda. Prior to this, she completed her M.Sc. in Biotechnology (87.07%) from the College of Basic Science and Humanities, OUAT, Bhubaneswar in 2018 and a B.Sc. in Biotechnology with distinction (75%) from Ramadevi Women’s College, Utkal University in 2016. Her academic journey showcases a strong foundation in both theoretical and applied aspects of biosciences.

💼 Experience:

Dr. Alaka Sahoo brings rich hands-on research experience in clinical and experimental biotechnology. She is skilled in BSL-2+ lab practices, molecular techniques like PCR, gel electrophoresis, microbial culture, ELISA-based diagnostics, and bioinformatics. Her doctoral work integrated multi-omics and computational biology to study inflammatory oral diseases, and her postdoctoral research spans drug delivery and antimicrobial drug discovery. As first or corresponding author in 7 out of 17 publications, she has led collaborative studies with both national and international partners. Dr. Sahoo’s cross-disciplinary knowledge in microbiology, pharmacology, and nanomedicine enhances her problem-solving abilities, making her a versatile researcher. Her ability to bridge clinical dermatology with biotechnology research positions her as an impactful contributor in both healthcare and academic environments.

🏆 Awards & Honors:

Dr. Alaka Sahoo has received notable accolades for her innovation and leadership in science. In 2024, she was awarded the Lalchand Women Entrepreneurs Award by the Odisha Corporate Foundation, recognizing her outstanding contributions in biotech innovation. She also earned the MSME-Idea Hackathon 3.0 (Women) Innovation Award by the Government of India, honoring her practical scientific advancements with societal impact. These awards reflect her dedication to translational research and her vision to develop cost-effective, natural therapies. Dr. Sahoo is also a life member of two esteemed organizations: the British Society for Antimicrobial Chemotherapy (UK) and Bioclues Innovation, Research and Development (India). Her achievements signify her rising prominence in the field and her commitment to addressing public health challenges through integrative research.

🔬 Research Focus:

Dr. Alaka Sahoo’s research focuses on oral inflammatory diseases, natural product therapeutics, and insect-derived peptides as alternatives to conventional antimicrobials. Her Ph.D. thesis explored multi-omics approaches for drug discovery in Oral Lichen Planus, integrating in vitro, in silico, and clinical data. Her work spans immunomodulation, anti-inflammatory drug screening, and nanodrug delivery systems, with cross-functional expertise in dermatology, pharmacology, and microbiology. She combines computational modeling, molecular docking, and wet-lab validation to develop target-specific therapies. Her studies on biofilm inhibition, antifungal peptides, and phytosteroids hold promise for tackling antimicrobial resistance. Through collaborations across academia and healthcare, she aims to translate her lab findings into clinically viable solutions. Her contributions to systematic reviews and molecular simulations further demonstrate her analytical rigor and commitment to evidence-based research.

📚 Publications Top Notes:

  1. 📘 Experimental and clinical trial investigations of phytoextracts in Oral Lichen Planus: A systematic review – J Ethnopharmacol (2022)

  2. 🐞 Insect-derived antimicrobial peptides as novel anti-biofilm agents: A systematic review – Front. Microbiol. (2021)

  3. 💊 Ultraflexible liposome nanocargo for dermal drug delivery – Nanomaterials (2021)

  4. 🌿 Phytochemicals for Oral Lichen Planus: A multi-omics and experimental study – Chem Biodivers (2025)

  5. ⚗️ Carbohydrate-derived N-benzyl aminocyclopentitols with anticancer properties – Carbohydr Res. (2025)

  6. 🧬 Target-specific screening of anti-inflammatory phytosteroids using molecular docking – Steroids (2025)

  7. 🧪 Insect-derived antifungal peptides in Candida management – Int. J. Mol. Sci. (2025)

  8. 🧫 Azo-coumarin-Co(II)-galangin hybrids for multipotential activities – J. Biomol. Struct. Dyn. (2024)

  9. 🧒 Pediatric dermatology case analysis in Eastern India – Indian J. Paediatr. Dermatol. (2024)

  10. 🔬 Schiff/Mannich coumarin derivatives: Antibacterial and anti-biofilm evaluation – RSC Adv. (2024)

🧾 Conclusion:

Dr. Alaka Sahoo is highly suitable for the Research for Young Researcher Award. Her multi-disciplinary expertise, robust research record, and recognition through national awards highlight her as a promising early-career scientist. She combines academic rigor with innovation, and her work has meaningful implications for public health, especially in oral disease therapy, biofilm inhibition, and phytochemical-based drug development.

Muhammad Junaid Anwar | Immunology Cellular Interactions | Best Researcher Award

Mr. Muhammad Junaid Anwar | Immunology Cellular Interactions | Best Researcher Award

Mr. Muhammad Junaid Anwar , Bahauddin Zakariya Univeristy Multan Pakistan , Pakistan

Dr. Muhammad Junaid Anwar is a dedicated food scientist specializing in Food Science and Technology. With a Ph.D. from Bahauddin Zakariya University (BZU), Multan, he has established himself as a researcher with expertise in food safety, nanotechnology, and functional foods. His work focuses on developing innovative solutions for food security, nutrition, and disease prevention. Having authored multiple high-impact research publications, Dr. Anwar’s contributions span across nanotechnology-based food encapsulation, food safety enhancement, and alternative protein sources. He has also participated in prestigious conferences and workshops, further showcasing his commitment to advancing food science. His research has significantly contributed to tackling food-related health challenges such as cow milk allergies, microbial contamination, and nutraceutical applications. With his profound knowledge, industry experience, and research excellence, Dr. Anwar stands out as a promising scholar in the field. His dedication to food innovation makes him a deserving candidate for the Best Researcher Award.

Publication Profile: 

Scopus

Strengths for the Award

  1. Strong Academic Background – Dr. Muhammad Junaid Anwar has an exceptional academic record with a Ph.D. in Food Science and Technology, a strong CGPA, and an extensive research focus.

  2. High-Impact Research Publications – He has authored multiple research articles in reputable, high-impact factor journals (Ultrasonics Sonochemistry, Food Science & Nutrition, Food Bioscience, etc.). His contributions cover diverse areas, including nanotechnology, food safety, and immunomodulation.

  3. Diverse Research Contributions – His research spans crucial topics such as nano-encapsulation, diabetes management, functional foods, and nutraceuticals, demonstrating interdisciplinary expertise.

  4. Industry Experience – His experience as an Officer in Quality Enhancement and Laboratory at S.M. Food Makers highlights his applied knowledge and practical contribution to food science.

  5. Conference Participation – He has actively contributed to scientific discussions through multiple national conferences, particularly on food security and food safety.

  6. Published Abstracts & Workshops – His engagement in published abstracts and workshops reflects an effort to bridge academia with real-world food technology applications.

Areas for Improvement

  1. International Collaboration – While his research is strong, expanding collaborations with international institutions and researchers could further enhance global impact.

  2. Patent & Commercialization – Translating research into patents or commercial food innovations would strengthen his practical contributions to the industry.

  3. Citations & Recognition – As some of his latest research articles have yet to gain citations, increasing visibility through academic networks and outreach can boost recognition.

Education:

Dr. Muhammad Junaid Anwar has an exceptional academic background in Food Science and Technology. He is currently completing his Ph.D. (2021-2025) at the Department of Food Science and Technology, BZU Multan, with a stellar CGPA of 3.87/4.00. Previously, he completed his M.Sc. (Hons.) in Food Science & Technology (2018-2020) from the same institution, securing a CGPA of 3.76/4.00. His undergraduate journey began with a B.Sc. (Hons.) in Agriculture (Food Science & Technology) (2014-2018), again with a CGPA of 3.76/4.00. His solid foundation in sciences started with F.Sc. (Pre-Medical) in 2014 from Muslim Public Higher Secondary School, Multan, achieving 840/1100 marks, followed by Matriculation in 2012 from Govt. M.A Jinnah High School, Multan, with 863/1050 marks. His consistent academic excellence highlights his dedication to food science research and technological advancements, making him a strong candidate for the Best Researcher Award.

Experience:

Dr. Muhammad Junaid Anwar has a diverse professional background in food science research and industry. He completed a 7-week internship at Bunny’s Limited, Lahore, where he gained hands-on experience in food processing and quality control. He later served as an Officer (Quality Enhancement and Lab) at S.M. Food Makers for two years (2018-2020), where he worked on ensuring food safety standards and enhancing product quality. His industry experience has provided him with a deep understanding of food technology applications, quality assurance, and research methodologies. In addition to his industry roles, he has contributed to academia through extensive research on food nanotechnology, functional foods, and microbial safety. His experience spans both applied and theoretical research, making him an asset to the food science community. His professional achievements, combined with his research excellence, make him a strong contender for the Best Researcher Award.

Research Focus:

Dr. Muhammad Junaid Anwar’s research revolves around food nanotechnology, functional foods, and food safety. His recent work focuses on the nano-encapsulation of bioactive compounds, such as casein-based encapsulation for managing cow milk allergies. His contributions extend to food safety enhancements using ultrasonication and calcium chloride treatments to reduce microbial contamination in fresh produce. Dr. Anwar has also explored the nutraceutical applications of medicinal plants like fenugreek and Tribulus terrestris to develop functional foods with health benefits. His studies have highlighted the role of alternative protein sources, such as Moringa oleifera-derived proteins, in plant-based meat substitutes. Additionally, he has worked on the impact of ozone treatment in mitigating mycotoxin contamination in food. His multi-disciplinary approach to food science integrates biotechnology, food engineering, and health sciences, making his research valuable for global food security and human health. His outstanding contributions make him a strong candidate for the Best Researcher Award.

Publications Top Notes:

📌 Casein-Based Nano-Encapsulation for Cow Milk Allergy Management 🥛🔬 (Food Bioscience, 2025)
📌 Ultrasonication & Calcium Chloride Pre-Treatment for Microbial Load Reduction in Carrots 🥕🦠 (Ultrasonics Sonochemistry, 2025)
📌 Isoflavones: Natural Agents for Cancer Prevention & Treatment 🎗️🍃 (Food Science & Nutrition, 2025)
📌 Functional Yogurt with Cinnamon & Stevia for Diabetes Management 🍦🍯 (Food & Agricultural Immunology, 2024)
📌 Nutritional & Physico-Chemical Profiling of Tribulus terrestris for Nutraceutical Applications 🌿💊 (Journal of Population Therapeutics & Clinical Pharmacology, 2024)
📌 The Multifaceted Potential of Fenugreek Seeds in Health & Nanotechnology 🌱⚗️ (Food Science & Nutrition, 2024)
📌 Protein Extraction from Moringa Leaves as a Plant-Based Meat Alternative 🍃🥩 (Regulatory Toxicology & Pharmacology, 2024)
📌 Role of Ozone in Mycotoxin Management for Food Safety ⚡🍞 (PSFST Conference, 2023)
📌 Potential of Anaerobic Digestion in Food Waste Management 🔄♻️ (PSFST Conference, 2023)
📌 Addressing Food Price Fluctuations: A Global Priority 📈🌍 (PSFST Conference, 2023)
📌 Strengthening Local Food Systems for Food Security 🌾🍽️ (PSFST Conference, 2023)

Conclusion:

Dr. Muhammad Junaid Anwar has demonstrated exceptional research contributions in food science, particularly in functional foods, nanotechnology, and food safety. His high-impact publications, active participation in conferences, and industry experience make him a strong candidate for the Best Researcher Award. Strengthening international collaborations and focusing on patents or commercialization could further enhance his research impact.

Ahmet Kor | Immunology Cellular Interactions | Best Researcher Award

Assoc. Prof. Dr. Ahmet Kor | Immunology Cellular Interactions | Best Researcher Award

Assoc. Prof. Dr. Ahmet Kor , aksaray university training and research hospital , Turkey

Dr. Ahmet Kor is an associate professor at the Department of Rheumatology, Aksaray Education and Research Hospital, Turkey. With a profound expertise in rheumatology, he has made significant contributions to biomarker-based research in various rheumatological diseases. Dr. Kor is well-known for his pioneering work in understanding the relationship between rheumatoid arthritis (RA) and interstitial lung disease, as well as his research on small vessel vasculitis and renal estrogen receptors. His work is highly regarded for its originality and depth in the study of biomarkers and disease mechanisms. Dr. Kor’s academic journey has seen him publish numerous journal articles, collaborate with global researchers, and gain recognition in the field. He is committed to advancing rheumatology research and improving clinical outcomes for patients with autoimmune diseases.

Publication Profile:

Orcid

Strengths for the Award:

Dr. Ahmet Kor’s impressive body of work in rheumatology, particularly his focus on biomarkers, places him as an ideal candidate for the “Best Researcher Award.” He has contributed significantly to understanding complex mechanisms in autoimmune diseases such as rheumatoid arthritis (RA) and primary Sjögren’s syndrome. Notably, his pioneering research into the relationship between RA and interstitial lung disease, as well as his exploration of estrogen receptors in small vessel vasculitis, has opened new avenues for diagnostics and treatment. With a remarkable publication record, Dr. Kor has demonstrated both depth and breadth in his research, having published 17 peer-reviewed articles in SCI-indexed journals. His research also bridges the gap between clinical practice and scientific exploration, which enhances its relevance. His ability to identify novel biomarkers like netrin-1 in various diseases showcases his innovative thinking and commitment to advancing rheumatology.

Areas for Improvements:

While Dr. Kor’s research is highly impactful, expanding the focus of his work to include larger-scale clinical trials could provide additional validation of his findings in broader populations. Furthermore, enhancing collaborations with research institutions worldwide could increase the global applicability of his discoveries. A more extensive exploration into therapeutic implications of his findings may also contribute significantly to clinical advancements.

Education:

Dr. Ahmet Kor completed his medical degree (MD) at a prestigious university in Turkey, focusing on the field of rheumatology. He then pursued specialized training and completed his residency in internal medicine before further refining his expertise in rheumatology. His educational background allowed him to develop a deep understanding of autoimmune diseases, particularly their biomarkers and disease progression. Throughout his academic career, Dr. Kor has engaged in continuous education and research, publishing books and numerous peer-reviewed journal articles. His research interests have evolved into studying the molecular mechanisms underlying rheumatological diseases, contributing valuable knowledge to both the academic and clinical communities. Dr. Kor’s educational foundation combined with his professional training has solidified his status as a leading expert in rheumatology, and he continues to inspire students and colleagues alike through his work and teachings.

Experience:

Dr. Ahmet Kor has significant experience in both clinical practice and academic research in rheumatology. He currently holds the position of associate professor at Aksaray Education and Research Hospital in Turkey, where he leads a team of researchers in exploring biomarker-based studies for rheumatological diseases. Over the years, Dr. Kor has worked extensively in clinical settings, diagnosing and treating various autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus, and small vessel vasculitis. His extensive research portfolio spans multiple domains, from interstitial lung diseases to novel biomarkers for autoimmune diseases. Dr. Kor has been involved in consulting for the pharmaceutical industry and collaborated with other research institutions globally. His experience extends beyond clinical practice, as he actively contributes to scientific journals, editorial roles, and academic committees. His ability to bridge research with clinical application allows him to make lasting contributions to the field of rheumatology.

Research Focus:

Dr. Ahmet Kor’s research focuses on the exploration of biomarkers in rheumatology, particularly in autoimmune diseases such as rheumatoid arthritis (RA) and small vessel vasculitis. His work aims to identify novel biomarkers that can predict disease progression, diagnose early-stage diseases, and guide therapeutic interventions. He has made significant discoveries regarding the relationship between RA-associated interstitial lung disease and netrin-1 levels, as well as the connection between small vessel vasculitis and renal estrogen receptors. Additionally, Dr. Kor’s research delves into the molecular mechanisms of disease, such as the thiol/disulfide balance in psoriatic arthritis and the potential role of estrogen receptors in primary Sjögren’s syndrome. His studies are instrumental in advancing personalized medicine in rheumatology, with the aim of improving diagnostic accuracy and therapeutic outcomes. Through his interdisciplinary research, Dr. Kor seeks to make impactful contributions to the understanding of autoimmune diseases and their biomarkers.

Publications Top Notes:

  • Urinary Total Superoxide Dismutase Activity in Rheumatoid Patients 🔬🧬

  • Does Eta Protein Differentiate Rheumatoid Arthritis from Psoriatic Arthritis? 🤔💉

  • Renal Tubular Estrogen ß Receptors in Small Vessel Vasculitis 🧑‍🔬🔬

  • Thiol/Disulfide Balance in Psoriatic Arthritis 🧪🧬

  • Ensemble Learning and Feature Selection in Diagnosis of Low Back Pain 💻🩺

  • Serum Netrin-1 Level in Rheumatoid Arthritis 🧪🔬

  • Estrogen Receptor ß in Minor Salivary Glands of Primary Sjögren’s Syndrome 🧑‍🔬💉

  • Serum Netrin-1 as a Potential Biomarker for Diabetic Peripheral Artery Disease 🩸💉

  • 14-3-3η Proteins in Primary Sjögren Syndrome 🧬💡

Conclusion:

Dr. Ahmet Kor is a distinguished researcher whose contributions to the field of rheumatology, particularly in biomarker-based studies, make him highly deserving of the “Best Researcher Award.” His innovative approach to understanding complex autoimmune diseases, combined with his extensive publications and collaborations, reflects his dedication to improving patient care and advancing the scientific understanding of rheumatology. His research offers significant potential for future breakthroughs, making him an outstanding candidate for this prestigious award.

Laure VINCENT | Immunology Cellular Interactions | Best Research Article Award

Dr. Laure VINCENT | Immunology Cellular Interactions | Best Research Article Award

Dr. Laure VINCENT, CHU de Montpellier , France

Dr. Laure Vincent is a distinguished hematologist at the CHU de Montpellier, specializing in clinical hematology. With a focus on multiple myeloma and stem cell transplantation, she is recognized for her extensive research and clinical expertise. She is affiliated with the Hôpital St Eloi, Montpellier, where she actively contributes to advancing treatments in hematologic malignancies. Dr. Vincent has a profound commitment to patient care and an established career in the hematology field, making notable contributions to both the scientific and medical communities.

Publication Profile: 

Google Scholar

Strengths for the Award:

  1. Extensive Research Contribution: Dr. Vincent has made significant contributions to the field of hematology, with numerous publications in renowned journals such as Leukemia, Bone Marrow Transplantation, Haematologica, and Blood Cancer Journal. Her research has focused on critical topics like multiple myeloma, hematopoietic stem cell transplantation, and the treatment of myelodysplastic syndromes.

  2. Innovative and Impactful Studies: Many of her studies highlight novel findings that contribute to the understanding and management of hematological diseases. For instance:

    • Her research on insulin as a myeloma cell growth factor (Leukemia, 2010) opened new avenues for treatment approaches.

    • The exploration of the therapeutic window for myeloma relapse after high-dose melphalan and stem cell transplantation (Oncotarget, 2012) shows an in-depth understanding of patient care in a post-transplant setting.

    • The retrospective study on hematopoietic stem cell transplantation in multiple myeloma patients from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (Biol Blood Marrow Transplant, 2015) has crucial implications for treatment strategies in myeloma.

  3. Multidisciplinary Collaboration: Dr. Vincent has worked extensively with international research teams, reflecting her ability to collaborate and contribute to large-scale studies and multicenter trials. This is evident in studies such as the ones published with the Société Française de Greffe de Moelle et de Thérapie Cellulaire and the Eurocord/ALWP-EBMT study.

  4. Comprehensive Educational Impact: In addition to her research, Dr. Vincent has contributed significantly to the education and training of healthcare professionals, particularly in oncology and hematology. Her work in developing educational content for nurses and students in the field of Onco-Hematology demonstrates her commitment to advancing clinical knowledge.

Areas for Improvement:

  1. Wider Dissemination of Findings: While Dr. Vincent’s research has been highly impactful within the specialized field of hematology, her findings could benefit from broader dissemination. This could include collaborations with non-medical fields or publishing findings in more general medical journals to reach a wider audience.

  2. Focus on Translational Research: Although Dr. Vincent’s research primarily focuses on clinical outcomes and therapies, incorporating more translational research—bridging the gap between bench and bedside—could further enhance her work. Research on biomarkers for early detection, for example, would benefit the field of personalized medicine.

  3. Long-Term Impact Studies: Some of Dr. Vincent’s studies are focused on the immediate or short-term effects of therapies. It would be valuable to see more research that addresses the long-term outcomes of treatments in hematological diseases, especially in terms of quality of life and survival rates over decades.

Education:

Dr. Vincent’s educational journey began with secondary studies at the Lycée International de Grenoble, where she earned a scientific baccalaureate with distinction in 1999. She then pursued her medical degree at the University of Grenoble (1999-2006), followed by specialized training in hematology. Dr. Vincent is fluent in English, holding Cambridge Certificates in Advanced and Proficiency English. Additionally, she holds certifications in business English and advanced clinical training in hematology.

Experience:

Dr. Laure Vincent has extensive clinical experience in the field of hematology, particularly in hematopoietic stem cell transplantation. She has contributed to several impactful research studies, focusing on treatments for hematological malignancies like multiple myeloma and myelodysplastic syndromes. Dr. Vincent has published extensively in reputable journals, authored chapters in medical books, and presented her work at various prestigious international conferences, demonstrating her authority in the field. She also serves as an educator, contributing to the training of future healthcare professionals.

Research Focus:

Dr. Vincent’s research primarily focuses on hematological cancers, including multiple myeloma, myelodysplastic syndromes, and stem cell transplantation. Her studies explore innovative therapies, relapse prevention strategies, and mechanisms of drug resistance in these malignancies. Notable research topics include the use of monoclonal antibodies, the role of the bone marrow microenvironment, and the improvement of outcomes following hematopoietic stem cell transplantation. Her work aims to develop targeted therapies to improve patient survival rates and quality of life.

Publications Top Notes:

  1. “Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation” (Leukemia, 2010) 🧬

  2. “Malignant plasma cells responsible for Multiple Myeloma relapse are detectable and survive seven days after high dose melphalan and stem cell transplantation” (Oncotarget, 2012) 🧪

  3. “Allo-SCT for philadelphia negative myeloproliferative neoplasms in blast phase” (Bone Marrow Transplant, 2014) 💉

  4. “HLA-matched Allogeneic SCT improves outcome of higher risk MDS” (Leukemia, 2015) 🩸

  5. “Drug metabolism and clearance system in tumor cells of patients with multiple myeloma” (Oncotarget, 2015) 💊

  6. “Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation” (Haematologica, 2015) 👩‍⚕️

  7. “Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia” (Leukemia, 2015) 🔬

  8. “Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study” (Biol Blood Marrow Transplant, 2015) 🏥

  9. “Autologous Stem Cell Transplantation For Relapsed/Refractory Diffuse Large B Cell Lymphoma” (Bone Marrow Transplant, 2015) 🔄

  10. “Bing-Neel syndrome as a rare complication of Waldenström’s macroglobulinemia” (Haematologica, 2015) 🧠

Conclusion:

Dr. Laure Vincent’s research is exceptional, with a proven track record in advancing knowledge and treatment options in hematology. Her ability to lead large-scale studies, her contributions to important clinical findings, and her dedication to educating future healthcare professionals make her highly deserving of the “Best Research Article Award.” While there is always room for expanding the scope of research to include more translational and long-term impact studies, her work undoubtedly stands out as a significant contribution to hematological science.